The Affordable Care Act has nearly died at least three times since the final bill took shape in 2010; with the re-election of Barack Obama, it is all systems go. But remember, the race to implement the program by 2014 is only the beginning, not the end, of health care reform.
Minutes after the major news networks called Ohio (and the Presidency) for Barack Obama on November 7, Rock Creek Policy’s Ian Spatz summed up the significance of the election for health care policy on Twitter: “ACA has now passed its 3rd test (passage, SCOTUS, re-election) and coverage expansion will be implemented in 2014.”
The impact of the Obama victory, of course, hasn’t been missed by anyone in the health care sector: the Affordable...
Gilead and Roche reflect on their experiences with a global initiative that delivered aligned regulatory decisions through joint hybrid inspections and synchronized review of post-approval changes.
The EMA has scheduled oral explanation meetings this week for Anavex’s blarcamesine and three other products that are nearing the end of the regulatory review cycle. These meetings usually represent the final chance for sponsors to persuade the agency that their product merits approval.
In this exclusive article with Peter Crowley, Secretary and Scientific Director of the BP Commission, you’ll discover how the BP is preparing for its landmark 2026 edition while strengthening its influence as a global bridge between science, regulation, and industry.
